ATBPF News and Press, Antibe Therapeutics From 08/15/22

Antibe Therapeutics Inc. press release ( OTCQX:ATBPF ): Q1 GAAP EPS of -$0.10 misses by $0.02 . The Company had an available cash balance and term deposits totaling $50.2 million. For further details see: Antibe Therapeutics Inc. GAAP EPS of -$0.10 misses by $0.0...

- Phase II acute pain program to initiate in September - Ended quarter with $50 million in cash and equivalents, providing over two years of runway Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide pla...

Antibe Therapeutics Inc. press release ( OTCQX:ATBPF ): FY GAAP EPS of -$0.50 misses by $0.06 . As of March 31, 2022, the Company had an available cash balance and term deposits totaling $54.8 million, compared to $72.0 million as at March 31, 2021. For further detai...

- Phase II acute pain program to initiate in early calendar Q4 2022 - Ended year with $55 million in cash and equivalents, providing over two years of runway Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sul...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the " Company "), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “ Warrant Extensio...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair o...

- $6.5 million all-cash transaction, including milestone payments - Enables exclusive focus on drug pipeline Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer ...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference b...

Antibe Therapeutics press release (OTCQX:ATBPF): FQ3 GAAP EPS of -$0.09. As of December 31, 2021, the Company had an available cash balance totaling $58.6 million, compared to $72.0 million as at March 31, 2021. The Company reported an available cash balance of $60.5 million for the quar...

- Acute pain clinical program for otenaproxesul initiating this quarter - Ended quarter with a $59 million cash position Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-gener...